GO-ON, 25 mg/2,5 ml

GO-ON, 25 mg / 2.5 ml, solution for injection, 1 pre-filled syringe

Medical component.
A sterile, pyrogen-free solution of sodium hyaluronate.
Sodium hyaluronate improves the condition of the synovial fluid and restores the properties of the synovial fluid.
It is used to supplement the deficiencies in the viscosity and elasticity of the synovial fluid in the joints and to alleviate the symptoms of osteoarthritis.

Composition

Each syringe contains 2.5 ml of 1% sodium hyaluronate solution, sodium chloride, sodium monohydrogen phosphate, sodium dihydrogen phosphate and water for injections.
Action

Intra-articular administration of sodium hyaluronate improves the condition of the synovial fluid and restores the viscoelastic properties of the synovial fluid. This increases the lubricating and shock-absorbing effect and reduces the mechanical stress on the joint. Thanks to this, the mobility of the joints is improved and pain is alleviated.
Indications

The GO-ON medical device is used:

to supplement the deficiencies in the viscosity and elasticity of the synovial fluid in the knee and shoulder joints.
for viscosupplementation of the remaining synovial joints,
in relieving the symptoms of osteoarthritis.

The method of using the medical device

The preparation should be administered only by qualified personnel who are familiar with the method of its use.
It is recommended to perform 5 injections at weekly intervals.
The preparation can be used to treat several joints at the same time.
Depending on the severity of the disease, the therapeutic effect after 5 injections may last more than 6 months. Therapeutic cycles may be repeated.
Rarely, local pain may occur after administration of the product. In order to avoid such discomfort, the patient should be instructed to limit the movements in the joint to which the preparation was administered.

Contraindications and precautions

Do not use if you are allergic to any of the ingredients of the product.
Do not use in inflammatory diseases of the joints such as rheumatoid arthritis or Bechterew’s disease.
Do not use after the expiry date.
Keep out of reach of children.

Possible side effects of the medical device

Rarely, urticaria-like skin rash and pruritus may occur. In this case, treatment should be discontinued and appropriate medical treatment given. Pain (usually transient after administration), swelling and exudation or infection at the injection site have been reported rarely. Patients may rarely report redness, warmth or a feeling of heaviness at the site of application.
Shock symptoms have been reported very rarely after administration of the preparation, but there is a possibility of an anaphylactic reaction. In such a case, the administration of the preparation should be discontinued, appropriate treatment should be provided and the patient monitored.

Using the product with other drugs

There is an incompatibility between sodium hyaluronate and quaternary ammonium salts such as benzalkonium chloride, which can be used as a skin disinfectant. The preparation must under no circumstances come into contact with such products or with medical or surgical equipment with which such products are used.
Pregnancy and breastfeeding

No teratogenic effects have been identified in animals, but safety in pregnant women has not been established. In lactating women, it is recommended that breast-feeding be discontinued for the duration of treatment.
Use in children and adolescents

Due to the lack of confirmation of safety for use in children, the preparation should be used with caution.
Manufacturer
ROTTAPHARM
ul Zgodna 3
Warsaw